Stoke Therapeutics (STOK) reported second quarter 2026 results that showed lower sales and a wider loss, at the same time as it filed a US$57.72 million shelf registration for 2,000,000 ESOP related shares.

Despite the wider quarterly loss and the ESOP related shelf registration, Stoke Therapeutics’ recent price action has stayed resilient, with a 1 year total shareholder return of about 150% and a very large 3 year total shareholder return, while the 1 day and 7 day share price returns of 2.44% and 13.34% hint at building momentum.

If you are assessing how this kind of volatility compares across the market, it can help to widen the lens and look at 43 healthcare AI stocks.

Bulls point to Stoke Therapeutics’ strong recent shareholder returns and late stage pipeline. Bears focus on the widened losses and possible dilution from the ESOP shelf. Which side does the current valuation evidence appear to support?

Most Popular Narrative: 27.5% Undervalued

Stoke Therapeutics last closed at $32.71, while the most widely followed narrative sets fair value at $45.10. That gap is built on ambitious growth and profitability assumptions that sit well beyond the current loss making position.

The analysts have a consensus price target of $45.1 for Stoke Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $177.8 million, earnings will come to $33.6 million, and it would be trading on a PE ratio of 125.9x, assuming you use a discount rate of 7.2%.

Want to understand why this narrative supports such a big gap between price and fair value? The story hinges on rapid top line expansion, a sharp swing into profitability and a premium earnings multiple usually reserved for standout growth stocks.

Result: Fair Value of $45.10 (UNDERVALUED)

However, the Stoke Therapeutics story could shift quickly if the Phase 3 Dravet data disappoints or if pricing and reimbursement push future margins below current assumptions.

Next Steps

With sentiment clearly split between risks and rewards around Stoke Therapeutics, it makes sense to move fast and test the numbers for yourself. To weigh both sides in one place, take a close look at the 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Stoke Therapeutics?

If you want to build on what you have learned about Stoke Therapeutics, use this moment to line up your next set of high conviction watchlist candidates.

• Spot opportunities other investors might overlook by scanning the screener containing 19 high quality undiscovered gems before they move out of reach.
• Strengthen your downside protection by focusing on companies highlighted in the 79 resilient stocks with low risk scores that may help smooth out portfolio swings.
• Target companies with cleaner finances by shortlisting ideas from the solid balance sheet and fundamentals stocks screener (49 results) while the market is still sorting the standouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.